MEET OUR TEAM

The DNAnexus team is made up of experts in software, computational biology, and genetics who are on a mission to unlock the potential for DNA-based medicine and biotechnology.

Leadership

Richard Daly

Richard Daly

Chief Executive Officer

Dick has three decades of experience in building companies in healthcare and genomics, including 13 years at Baxter Laboratories. Subsequently to Baxter, Dick founded companies in both managed care and laboratory services, and was also the CEO of Visible Genetics (NASDAQ: VGIN), the pioneer in laboratory-based gene sequencing and bioinformatics. Education includes a BS in finance from New York University and an MBA from Harvard University.

George Asimenos, PhD

George Asimenos, PhD

Chief Technology Officer

Part of DNAnexus since its inception, George has been involved in the design and implementation of the DNAnexus product line, and its application in key accounts around the world. He is currently heading up strategic projects, exploring ways in which DNAnexus technology can be used to craft novel experiences that transcend traditional genomics boundaries. George holds a PhD in computer science from Stanford University, where he helped analyze 1% of the human genome as part of the ENCODE Pilot Project. His prior research experience includes comparative metagenomics, silicon compilers for reconfigurable hardware, and elliptic curve cryptanalysis.

Andrew Carroll, PhD

Andrew Carroll, PhD

Vice President, Science

Andrew works with a team of DNAnexus scientists on engagements with customers in clinical diagnostics, pharmaceutical R&D, and academia. He helped to run the largest cloud genomics project, conducted with the CHARGE Consortium and Baylor College of Medicine, covering 20,000 genomes/exomes, and the largest plant genomics project conducted thus far covering 3,000 rice genomes in the 3000 Rice Genomes Project. Through the work of the science team at DNAnexus, he has worked on clinical and research projects with SNP and indel calling in individuals and large cohorts, expression analysis, structural variant analysis, genome assembly, tumor-normal analysis, computational chemistry, and image processing. He received his PhD from Stanford University and his academic work involved comparative genomics in plants, proteomics, and machine learning.

Brady Davis

Brady Davis

Vice President, Strategy & Marketing

Brady brings over 15 years experience as an innovator and leader in the life sciences space as well as the hospital ACO and consumer health and wellness industries. Prior to DNAnexus, Brady was head of strategy and market development for Illumina with a special focus on Informatics and driving opportunities to use genetics data as clinical utility. Brady serves on the board of multiple non-profit organizations including the Global Alzheimer's Association Interactive Network (GAAIN), Cancer Commons, Ci4CC, and is Co-Chair of the Advisory Board for the University of Washington Center for Commercialization (C4C). Brady is a graduate of University of Washington.

John Ellithorpe, PhD

John Ellithorpe, PhD

Chief Product Officer

John is an experienced executive who is passionate about improving people's lives through innovative technology. Most recently, John was CPO at Vantiq delivering intelligent systems in the IoT space, and co-founder, CTO, and CPO at Model N (NYSE: MODN) where he led the Global Products group and drove the technical strategy. John earned a Bachelor of Science in Physics from the University of California at Irvine and a PhD in Physics from the Massachusetts Institute of Technology.

Fan Fan, PhD

Fan Fan, PhD

Vice President Product Management

Fan works closely with prospects, customers, and the DNAnexus team to drive product vision and strategy. Fan joins DNAnexus from Adobe, where she served as Principal of Product Management responsible for cloud-based document productivity services. Prior to Adobe, she led Product Management at Model N, directly engaging with some of the world's largest pharmaceutical and biotechnology companies, including Merck and Amgen. Fan earned a Bachelor's degree in Biology at the University of Science and Technology of China, and a Ph.D. in Molecular Biology from the University of Southern California.

Kelly Green

Kelly Green

Head of People Operations

Kelly serves as the Head of People Operations where she leads DNAnexus' efforts in all things "people”. She is primarily responsible for talent acquisition, employee growth and development, building a great culture, and facilitating organizational development. Kelly joined DNAnexus after leading the HR efforts at Telenav, another disruptive technology company in Silicon Valley. There, Kelly led the HR efforts from venture-backed “start up” through a successful IPO. Kelly holds a Bachelor's in Psychology from Stonehill College.

Laura Kulick

Laura Kulick

Controller

Laura brings two decades of experience in developing and growing the accounting function and teams in high-tech startup companies. Laura comes most recently from Ingenuity Systems where she was the Controller during an acquisition by Qiagen, inc. Prior, Laura worked at companies from the initial startup stages through IPO. Laura holds a Bachelor of Science in Accountancy from Miami University.

Andrew Lim, PhD

Andrew Lim, PhD

Vice President and General Manager, Asia Pacific

Andrew is responsible for the company's overall business in Asia, Australia and New Zealand. Previously, Andrew has held senior positions at several cloud companies, including Sentient Technologies and Tendril. He was also responsible for business development, corporate development and strategy with Telstra and with Seagate Technology, where activities were focused broadly across the Asia Pacific region. Prior to that, he was a management consultant at the Boston Consulting Group. Andrew holds a BSc (Hons) from the University of Sydney and a Ph.D. from the University of California, Berkeley.

Michael F. Lin, PhD

Michael F. Lin, PhD

Vice President of Research and Development

Mike leads R&D engineering, working with customers and partners to deploy cutting-edge software and algorithms enabling the translation of genomic data into precision medicine. He previously led cloud systems engineering during initial development of the DNAnexus Platform, after studying computational comparative genomics at MIT and the Broad Institute.

Tim O'Brien

Tim O'Brien

Vice President, Sales

Tim brings over 20 years experience in enterprise software sales to the management team. He has built and led sales organizations and managed strategic customer relations within the life science and healthcare industries. At Oracle, Tim led the America's healthcare sales organization for the HSGBU, managed life science and translational research sales teams at ID Business Solutions, and held key bioinformatics sales and sales management positions at InforMax/Life Technologies. Tim holds a BA from the University of Colorado at Boulder.

Omar Serang

Omar Serang

Chief Cloud Officer

Omar has decades of experience building global operations teams and infrastructures, including cloud computing at Amazon Web Services, social web real-time analysis services at Topsy Labs, and messaging and messaging security services at Cloudmark and Critical Path. Prior to joining DNAnexus, Omar developed the Enterprise I/T Cloud Transformation consulting practice at Amazon Web Services, working with global pharmaceutical, manufacturing, and entertainment companies to drive cloud adoption. Omar received his BS in Chemistry from UC Berkeley.

David Shaywitz, MD, PhD

David Shaywitz, MD, PhD

Chief Medical Officer

As Chief Medical Officer, David is responsible for driving clinical impact, working closely with management and engineering teams, and with external partners and collaborators. Most recently at Theravance Biopharma, David focused on strategy and business development, and led a product team. Prior, he was a management consultant at the Boston Consulting Group, and was an early member of the Department of Experimental Medicine at Merck Research Labs. He was also a founding advisor of Sage Bionetworks, and a co-founder of the MGH/MIT Center for Assessment Technology and Continuous Health (CATCH). David received his M.D. from the Harvard-MIT Division of Health, Science, and Technology at Harvard Medical School, and his Ph.D. from the Department of Biology at MIT. He trained in internal medicine and endocrinology at the Massachusetts General Hospital, and conducted his post-doctoral research in Doug Melton's lab at the Harvard Stem Cell Institute.

Brad Sitko

Brad Sitko

Vice President, Finance & Corporate Development

Brad brings over a decade of experience in corporate strategy, business development, capital raising and M&A in life sciences to DNAnexus. Most recently, Brad was a healthcare investment banker at MTS Health Partners executing over 25 diverse transactions accounting for $7B of M&A volume and capital raised. Prior, Brad worked in business development and strategic planning at Pfizer. Prior to that, as a strategy consultant, he advised biotech companies on strategic planning, commercialization and market development strategies at Frankel Group. Brad holds a BA from Penn and an MBA from Columbia Business School.

Board of Directors

Michael Goldberg

Michael Goldberg

Executive Chairman DNAnexus

During a career spanning 30 years, Michael Goldberg has been a company founder, CEO, board member and venture capitalist. Presently, he serves as Executive Chairman of several venture-backed companies. Michael joined the life science industry in 1981 and participated in the commercialization of the first generation of recombinant DNA, monoclonal antibody and PCR technology. Michael holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.

Richard Daly

Richard Daly

CEO

Dick has three decades of experience in building companies in healthcare and genomics, including 13 years at Baxter Laboratories. Subsequently to Baxter, Dick founded companies in both managed care and laboratory services, and was also the CEO of Visible Genetics (NASDAQ: VGIN), the pioneer in laboratory-based gene sequencing and bioinformatics. Education includes a BS in finance from New York University and an MBA from Harvard University.

Geoffrey Duyk, M.D., Ph.D.

Geoffrey Duyk, M.D., Ph.D.

Managing Director and Partner TPG Biotechnology / TPG Alternative and Renewable Technologies

Dr. Duyk co-leads TPG Biotechnology group managing $1.1 bn in capital and is the lead partner in TPG's Alternative and Renewable Technology sector. Prior to joining TPG Biotech, Dr. Duyk served on the Board of Directors and was President of Research & Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and Assistant Professor at Harvard Medical School. Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University and completed his medical and fellowship training at UCSF.

Nat Goldhaber

Nat Goldhaber

Managing Director

Nat is a managing director and co-founder of Claremont Creek Ventures. Nat has twenty five years experience in IT and IT management: founder and CEO of Centram Systems West (TOPS), CEO of Cybergold, founding CEO of Kaledia Labs and Vice President of Sun Microsystems. Nat holds a Master's degree and PhD (h.c.) in Education. Nat is an emeritus member of the Executive Board of the College of Letters and Science at UC Berkeley and the Board of the Federation of American Scientists.

Edward Hu

Edward Hu

CFO and CIO, WuXi AppTec

Over the past decade, Edward Hu has held various leadership positions at WuXi. He currently manages WuXi AppTec's finance, investments, mergers and acquisitions, joint ventures, new business and capability building, and is Head of WuXi Corporate Venture Fund. Prior to joining WuXi, Edward was SVP and COO of Tanox, and managed the company’s acquisition by Genentech. He has also held positions at Merck & Co., Inc. and Biogen, Inc. Edward completed his PhD work in Biophysics and Biochemistry at Carnegie Mellon University, where he also received his MBA.

Ge Li

Ge Li

Founder, Chairman, and CEO of WuXi AppTec

A pioneer in the biopharma R&D service industry in China, Dr. Ge Li founded WuXi in December 2000. During the past 16 years as the company’s Chairman and CEO, Dr. Li has led WuXi’s rapid growth into a global R&D enabling powerhouse. Dr. Li's visionary leadership and achievements have won him numerous prestigious awards and honors, including most recently the 2016 CBA Brilliant Achievement Award, 2015 SCRIP Executive of the Year Award, and 2015 FierceBiotech 25 Most Influential People in Biopharma. Dr. Li hold a BS in Chemistry from Peking University and PhD in Organic Chemistry from Columbia University.

Arend Sidow, PhD

Arend Sidow, PhD

Board Observer, DNAnexus

Arend is an Associate Professor of Pathology and Genetics at Stanford University. His research focuses on functional and variation genomics, and he has many years of first-hand experience with DNA sequence generation and analysis. He is also Director of Computation at the Stanford Center for Genomics and Personalized Medicine.

Hannes Smarason

Hannes Smarason

President and COO, WuXi NextCODE

Hannes is co-founder, president and COO of WuXi NextCODE. A serial entrepreneur, he served previously as CFO and executive VP of business and finance at deCODE genetics, which during his tenure achieved global recognition as the leader in analyzing and understanding the human genome. Hannes received his master's in management from MIT, where he also earned his bachelor's in mechanical engineering.

Krishna Yeshwant, M.D.

Krishna Yeshwant, M.D.

General Partner, Google Ventures

Dr. Krishna Yeshwant is a physician, programmer, and entrepreneur who has been working with Google Ventures since its inception. Prior to Google he helped start an electronic data interchange company that was acquired by Hewlett-Packard (HP) and a network security company that was acquired by Symantec (SYMC). Krishna has a BS in Computer Science from Stanford University. He also earned an MD from Harvard Medical School and an MBA from Harvard Business School. He completed his residency at Brigham and Women's Hospital in Boston, MA.

Scientific Advisory Board

Evan Eichler, PhD

Evan Eichler, PhD

Professor of Genome Sciences University of Washington

Elaine Mardis, PhD

Elaine Mardis, PhD

Co-Director of Technology Development Genome Institute, Washington University

Rick Myers, PhD

Rick Myers, PhD

President, Director, and Investigator HudsonAlpha Institute for Biotechnology

Eddy Rubin, PhD

Eddy Rubin, PhD

Director DOE Joint Genome Institute

Gavin Sherlock, PhD

Gavin Sherlock, PhD

Associate Professor Stanford University

Computational Advisory Board

Emmanouil Dermitzakis, PhD

Emmanouil Dermitzakis, PhD

Louis-Jeantet Professor of Genetics University of Geneva Medical School

Mark Gerstein, PhD

Mark Gerstein, PhD

Professor of Biomedical Informatics, Molecular Biophysics & Biochemistry and Computer Science Yale University

Roderic Guigo, PhD

Roderic Guigo, PhD

Associate Professor
Universitat Pompeu Fabra

Eran Halperin, PhD

Eran Halperin, PhD

Associate Professor
Tel Aviv University

Jeff Heer, PhD

Jeff Heer, PhD

Associate Professor Computer Science and Engineering University of Washington

Sorin Istrail, PhD

Sorin Istrail, PhD

Professor of Computer Science
Brown University

Manolis Kellis, PhD

Manolis Kellis, PhD

Associate Professor MIT Computer Science and Electrical Engineering Department

Jill Mesirov, PhD

Jill Mesirov, PhD

Associate Director and Chief Informatics Officer Broad Institute

William Noble, PhD

William Noble, PhD

Professor, Department of Genome Sciences University of Washington

Pavel Pevzner, PhD

Pavel Pevzner, PhD

Director, Professor of Computer Science NIH Center for Computational Mass Spectrometry

Jonathan Pritchard, PhD

Jonathan Pritchard, PhD

Professor, Genetics Stanford University

Cenk Sahinalp, PhD

Cenk Sahinalp, PhD

Director Simon Fraser University Lab for Computational Biology

Steven Salzberg, PhD

Steven Salzberg, PhD

Professor Departments of Medicine and Biostatistics, Johns Hopkins Institute of Genetics Medicine

MAJOR INVESTORS

Google Ventures
TPG Biotech
Claremont Creek Ventures
WuXi NextCODE